Yes – 340B ESP
Yes (reach out to firstname.lastname@example.org to apply for the exemption)
Policy currently only applies to these products:
ANDROGEL® CREON® DEPAKOTE® DUOPA® GENGRAF® HUMIRA® KALETRA® K-TAB® LUPRON® MAVYRET® NIASPAN® NIMBEX® NORVIR® ORIAHNN® ORILISSA® RINVOQ® SYNTHROID® SKYRIZI® SURVANTA® TRICOR® TRILIPIX® ULTANE® VIEKIRA PAK® ZEMPLAR® Imbruvica (effective 4/1/22)
Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.
Q: If my organization does not provide 340B claims data by the required date, can it elect to do so at a later date and gain access to 340B pricing for contract pharmacies? If an entity begins to supply data after February 1, 2022, it must provide data for contract pharmacy dispenses to eligible patients in the prior 45-day period. Once the required data submission has been made, AbbVie will facilitate bill to/ ship to contract pharmacy replenishment orders on product dispensed to eligible patients from and after the date of data submission as well as the prior 45-day period.